Search
FDA Grants Orphan Drug Designation to Opaganib in Neuroblastoma
- OPACC
- Sep 13, 2024
- 1 min read
The FDA has granted a second orphan drug designation to opaganib in oncology, this time for patients with neuroblastoma.
Recent Posts
See AllDuring cancer treatment, children can face hurdles to maintaining healthy eating. Chemotherapy has many side effects, including loss of...
Quality of life improvements can be made if clinicians better understand auditory attention decay after cancer treatment in pediatric...
A team of experts, issuing a statement on behalf of the American Heart Association, have detailed cardiometabolic considerations for...
Comments